Seize the opportunity
- 26 August 2009
- journal article
- review article
- Published by Wiley in Cancer Cytopathology
- Vol. 117 (5) , 289-297
Abstract
Molecularly targeted agents are increasingly utilized to treat cancer. Unfortunately, biomarkers to guide this therapy are infrequently applied to FNA samples.Keywords
This publication has 35 references indexed in Scilit:
- Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic ConsiderationsJournal of Clinical Oncology, 2009
- Quantitative, Fluorescence-Based In-Situ Assessment of Protein Expression2009
- The cancer biomarker problemNature, 2008
- Applications of molecular techniques to fine-needle aspiration biopsyCancer, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant TrialJournal of Clinical Oncology, 2006
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999